US20050065185A1 - Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands - Google Patents

Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands Download PDF

Info

Publication number
US20050065185A1
US20050065185A1 US10/949,061 US94906104A US2005065185A1 US 20050065185 A1 US20050065185 A1 US 20050065185A1 US 94906104 A US94906104 A US 94906104A US 2005065185 A1 US2005065185 A1 US 2005065185A1
Authority
US
United States
Prior art keywords
ylmethoxy
optionally substituted
alkyl
sulfonyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/949,061
Inventor
Yanfang Li
Ping Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Priority to US10/949,061 priority Critical patent/US20050065185A1/en
Publication of US20050065185A1 publication Critical patent/US20050065185A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Definitions

  • 5-HT neurotransmitter 5-hydroxytryptamine
  • serotonin is localized in the central and peripheral nervous systems and is known to affect many types of conditions including psychiatric disorders, motor activity, feeding behavior, sexual activity, and neuroendocrine regulation among others.
  • the effects of serotonin are regulated by the various 5-HT receptor subtypes.
  • 5-HT receptors include the 5-HT1 family (e.g. 5-HT1A), the 5-HT2 family (e.g. 5-HT2A), 5-HT3, 5-HT4, 5-HT5, 5-HT6 and 5-HT7 subtypes.
  • 5-HT6 receptor subtype The recently identified human 5-hydroxytryptamine-6 (5-HT6) receptor subtype has been cloned, and the extensive distribution of its mRNA has been reported. Highest levels of 5-HT6 receptor mRNA have been observed in the olfactory tubercle, the striatum, nucleus accumbens, dentate gyrus and CA1, CA2 and CA3 regions of the hippocampus. Lower levels of 5-HT6 receptor mRNA were seen in the granular layer of the cerebellum, several diencephalic nuclei, amygdala and in the cortex. Northern blots have revealed that 5-HT6 receptor mRNA appears to be exclusively present in the brain, with little evidence for its presence in peripheral tissues.
  • 5-HT6 receptor ligands are believed to be of potential use in the treatment of certain CNS disorders such as anxiety, depression, epilepsy, obsessive compulsive disorders, attention deficit disorder, migraine, cognitive memory enhancement (e.g. for the treatment of Alzheimer's disease), sleep disorders, feeding disorders (e.g. anorexia and bulimia), panic attacks, withdrawal from drug abuse (e.g. cocaine, ethanol, nicotine and benzodiazepines), schizophrenia, or the like; or in the treatment of certain gastrointestinal disorders such as irritable bowel syndrome.
  • CNS disorders such as anxiety, depression, epilepsy, obsessive compulsive disorders, attention deficit disorder, migraine, cognitive memory enhancement (e.g. for the treatment of Alzheimer's disease), sleep disorders, feeding disorders (e.g. anorexia and bulimia), panic attacks, withdrawal from drug abuse (e.g. cocaine, ethanol, nicotine and benzodiazepines), schizophrenia, or the like; or in the treatment of certain gastrointestinal disorders such as irritable bowel
  • the compounds provided may also be used to further study and elucidate the 5-HT6 receptor.
  • the present invention provides a compound of formula I wherein
  • the present invention also provides methods and compositions useful for the therapeutic treatment of central nervous system disorders related to or affected by the 5-HT6 receptor.
  • the present invention further provides a method for the preparation of compounds of formula I and a compound useful therefor.
  • the 5-hydroxytryptamine-6 (5-HT6) receptor is one of the most recent receptors to be identified by molecular cloning. Its ability to bind a wide range of therapeutic compounds used in psychiatry, coupled with its intriguing distribution in the brain has stimulated significant interest in new compounds which are capable of interacting with or affecting said receptor. At present, there are no known fully selective agonists. Significant efforts are being made to understand the possible role of the 5-HT6 receptor in psychiatry, cognitive dysfunction, motor function and control, memory, mood and the like. To that end, compounds which demonstrate a binding affinity for the 5-HT6 receptor are earnestly sought both as an aid in the study of the 5-HT6 receptor and as potential therapeutic agents in the treatment of central nervous system disorders.
  • heterocyclylalkoxy-, -thioxy- or -aminobenzazole derivatives of formula I demonstrate 5-HT6 affinity.
  • said benzazole derivatives may be used as effective therapeutic agents for the treatment of central nervous system (CNS) disorders associated with or affected by the 5-HT6 receptor.
  • CNS central nervous system
  • the present invention provides heterocyclylalkoxy-, -alkylthio- or -alkylaminobenzazole derivatives of formula I wherein
  • halogen designates Br, Cl, I or F
  • cycloheteroalkyl designates a C 5 -C 7 cycloalkyl ring system containing 1 or 2 heteroatoms, which may be the same or different, selected from N, O or S and optionally containing one double bond.
  • exemplary of the cycloheteroalkyl ring systems included in the term as designated herein are the following rings wherein X 1 is NR, O or S.
  • heteroaryl designates a 5- to 10-membered aromatic ring system containing 1 or 2 heteroatoms, which may be the same or different, selected from N, O or S.
  • heteroaryl ring systems include pyrrolyl, azolyl, oxazolyl, thiazolyl, imidazolyl, furyl, thienyl, quinolinyl, isoquinolinyl, indolinyl, benzothienyl, benzofuranyl, benzisoxazolyl or the like.
  • haloalkyl designates a C n H 2n+1 group having from one to 2n+1 halogen atoms which may be the same or different and the term haloalkoxy as used herein designates an OC n H 2n+1 group having from one to 2n+1 halogen atoms which may be the same or different.
  • C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl, cycloheteroalkyl, phenyl or heteroaryl are designated as being optionally substituted
  • the substituent groups which are optionally present may be one or more of those customarily employed in the development of pharmaceutical compounds or the modification of such compounds to influence their structure/activity, persistence, absorption, stability or other beneficial property.
  • substituents include halogen atoms, nitro, cyano, thiocyanato, cyanato, hydroxyl, alkyl, haloalkyl, alkoxy, haloalkoxy, amino, alkylamino, dialkylamino, formyl, alkoxycarbonyl, carboxyl, alkanoyl, alkylthio, alkylsuphinyl, alkylsulphonyl, carbamoyl, alkylamido, phenyl, phenoxy, benzyl, benzyloxy, heterocyclyl or cycloalkyl groups, preferably halogen atoms or lower alkyl groups.
  • substituents preferably, 0-3 substituents may be present.
  • any of the foregoing substituents represents or contains an alkyl substituent group, this may be linear or branched and may contain up to 12, preferably up to 6, more preferably up to 4 carbon atoms.
  • Pharmaceutically acceptable salts may be any acid addition salt formed by a compound of formula I and a pharmaceutically acceptable acid such as phosphoric, sulfuric, hydrochloric, hydrobromic, citric, maleic, malonic, mandelic, succinic, fumaric, acetic, lactic, nitric, sulfonic, p-toluene sulfonic, methane sulfonic acid or the like.
  • a pharmaceutically acceptable acid such as phosphoric, sulfuric, hydrochloric, hydrobromic, citric, maleic, malonic, mandelic, succinic, fumaric, acetic, lactic, nitric, sulfonic, p-toluene sulfonic, methane sulfonic acid or the like.
  • Compounds of the invention may exist as one or more stereoisomers.
  • the various stereoisomers include enantiomers, diastereomers, atropisomers and geometric isomers.
  • one stereoisomer may be more active or may exhibit beneficial effects when enriched relative to the other stereoisomer(s) or when separated from the other stereoisomer(s). Additionally, the skilled artisan knows how to separate, enrich or selectively prepare said stereoisomers.
  • the present invention comprises compounds of Formula I, the stereoisomers thereof and the pharmaceutically acceptable salts thereof.
  • the compounds of the invention may be present as a mixture of stereoisomers, individual stereoisomers, or as an opticaly active form.
  • Preferred compounds of the invention are those compounds of formula I wherein W is SO 2 or CO. Also preferred are those compounds of formula I wherein X is O. Another group of preferred compounds of the invention are those compounds of formula I wherein Y is CR 14 .
  • R 12 is an aryl or heteroaryl group each optionally substituted; and n is 1.
  • More preferred compounds of the invention are those compounds of formula I wherein W is SO 2 ; X is O; and n is 1.
  • Another group of more preferred compounds of the invention are those compounds of formula I wherein W is SO 2 ; X is O; Y is CR 14 ; n is 1; and p is 1.
  • Compounds of the invention may be prepared using conventional synthetic methods and, if required, standard separation and isolation techniques.
  • compounds of formula I wherein W is SO 2 ; X is O; Y is CR 13 ; Z is CR 14 ; and R 4 and R 11 are H (Ia) may be prepared by reacting an hydroxyindole of formula II with an N-protected-2-methoxyheterocycle of formula III in the presence of triphenylphosphine and diethyl azodicarboxylate to give the corresponding indol-4-yloxyalkylheterocycle of formula IV. Subsequent sulfonylation and deprotection of the formula IV compound gives the desired formula Ia product.
  • the reaction sequence is illustrated in flow diagram I wherein P represents a protecting group.
  • Commonly used protecting groups include t-butyl-carboxylate, benzyl, acetyl, benzyloxycarbonyl, or any conventional group known to protect a basic nitrogen in standard synthetic procedures.
  • Compounds of formula I wherein W is SO 2 ; X is O; Y is CH; Z is N and R 4 and R 11 are H (Ib) may be prepared by reacting a nitromethylphenol of formula V with an N-protected-2-alkoxyheterocyclic compound of formula III in the presence of triphenylphosphine and diethyl azodicarboxylate to give the corresponding heterocyclylalkoxybenzene of formula VI, reducing the nitro group of the formula VI compound, for example via catalytic hydrogenation, to give the amine of formula VII and reacting the formula VII amine with isoamylnitrite in the presence of potassium acetate and acetic anhydride to give the heterocyclyalkoxyindazole of formula VIII.
  • Compounds of formula I wherein W is CO may be prepared by reacting the benzazole precursor, for example a compound of formula IV, VIII, XIII or XV with the appropriate isocyanate, carbonyl halide or carbamoyl halide in the presence of a base.
  • compounds of formula I wherein W is (CH 2 ) x and x is an integer of 1, 2 or 3 may be prepared by reacting the appropriately substituted alkylhalide with a compound of formula IV, VIII, XIII or XV in the presence of a base.
  • the present invention provides a compound of formula XVI wherein X, Y, Z, m, n, p, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and R 11 are as defined for formula I.
  • Compounds of formula XVI are useful in the preparation of the therapeutic agents of formula I described hereinabove.
  • the present invention also provides a method for the preparation of a compound of formula I wherein W is SO 2 (Ie) which comprises reacting a formula XVI compound with a sulfonyl chloride, R 12 SO 2 Cl, wherein R 12 is as defined for formula I in the presence of a base optionally in the presence of a solvent.
  • the reaction is shown in flow diagram V.
  • Bases suitable for use in the method of invention are strong bases such as NaH, KOt-Bu, or any conventional base capable of removing a proton from a basic indole or benzazole nitrogen-atom.
  • the inventive compound of formula I may be utilized in the treatment of central nervous system disorders relating to or affected by the 5-HT6 receptor such as motor, mood, psychiatric, cognitive, neurodegenerative, or the like disorders, for example, Alzheimer's disease, Parkinson's disease, attention deficit disorder, anxiety, epilepsy, depression, obsessive compulsive disorder, migraine, sleep disorders, feeding disorders (such as anorexia or bulimia), schizophrenia, memory loss, disorders associated with withdrawl from drug abuse, or the like or certain gastrointestinal disorders such as irritable bowel syndrome.
  • the present invention provides a method for the treatment of a disorder of the central nervous system (CNS) related to or affected by the 5-HT6 receptor in a patient in need thereof which comprises providing said patient a therapeutically effective amount of a compound of formula I as described hereinabove.
  • the compounds may be provided by oral or parenteral administration or in any common manner known to be an effective administration of a therapeutic agent to a patient in need thereof.
  • the therapeutically effective amount provided in the treatment of a specific CNS disorder may vary according to the specific condition(s) being treated, the size, age and response pattern of the patient, the severity of the disorder, the judgment of the attending physician and the like.
  • effective amounts for daily oral administration may be about 0.01 to 1,000 mg/kg, preferably about 0.5 to 500 mg/kg and effective amounts for parenteral administration may be about 0.1 to 100 mg/kg, preferably about 0.5 to 50 mg/kg.
  • the compounds of the invention are provided by administering the compound or a precursor thereof in a solid or liquid form, either neat or in combination with one or more conventional pharmaceutical carriers or excipients. Accordingly, the present invention provides a pharmaceutical composition which comprises a pharmaceutically acceptable carrier and an effective amount of a compound of formula I as described hereinabove.
  • Solid carriers suitable for use in the composition of the invention include one or more substances which may also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aides, binders, tablet-disintegrating agents or encapsulating materials.
  • the carrier may be a finely divided solid which is in admixture with a finely divided compound of formula I.
  • the formula I compound may be mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired. Said powders and tablets may contain up to 99% by weight of the formula I compound.
  • Solid carriers suitable for use in the composition of the invention include calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidine, low melting waxes and ion exchange resins.
  • any pharmaceutically acceptable liquid carrier suitable for preparing solutions, suspensions, emulsions, syrups and elixirs may be employed in the composition of the invention.
  • Compounds of formula I may be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, or a pharmaceutically acceptable oil or fat, or a mixture thereof.
  • Said liquid composition may contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, coloring agents, viscosity regulators, stabilizers, osmo-regulators, or the like.
  • liquid carriers suitable for oral and parenteral administration include water (particularly containing additives as above, e.g., cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols, e.g., glycols) or their derivatives, or oils (e.g., fractionated coconut oil and arachis oil).
  • the carrier may also be an oily ester such as ethyl oleate or isopropyl myristate.
  • compositions of the invention which are sterile solutions or suspensions are suitable for intramuscular, intraperitoneal or subcutaneous injection. Sterile solutions may also be administered intravenously.
  • Inventive compositions suitable for oral administration may be in either liquid or solid composition form.
  • NMR nuclear magnetic resonance
  • THF and EtOAc designate tetrahydrofuran and ethyl acetate, respectively.
  • the purified oil (5.05 g) is dissolved in ethanol, treated with 40% aqueous NaOH, heated at reflux temperature for 45 min, cooled in an ice-water bath, neutralized to pH 8 with concentrated HCl and concentrated in vacuo to remove the ethanol.
  • the resultant aqueous residue is extracted with EtOAc.
  • the combined extracts are washed sequentially with water and brine, dried over MgSO 4 and concentrated in vacuo to give a yellow oil.
  • This oil is purified by chromatography (silica gel, EtOAc:hexanes, 30:70) to give the title product as an off-white solid, 3.52 g, mp 125° C., identified by NMR and mass spectral analyses.
  • the affinity of test compounds for the serotonin 5-HT6 receptor is evaluated in the following manner. Cultured Hela cells expressing human cloned 5-HT6 receptors are harvested and centrifuged at low speed (1,000 ⁇ g) for 10.0 min to remove the culture media. The harvested cells are suspended in half volume of fresh physiological phosphate buffered saline solution and recentrifuged at the same speed. This operation is repeated. The collected cells are then homogenized in ten volumes of 50 mM Tris.HCl (pH 7.4) and 0.5 mM EDTA. The homogenate is centrifuged at 40,000 ⁇ g for 30.0 min and the precipitate is collected.
  • the obtained pellet is resuspended in 10 volumes of Tris.HCl buffer and recentrifuged at the same speed.
  • the final pellet is suspended in a small volume of Tris.HCl buffer and the tissue protein content is determined in aliquots of 10-25 ⁇ l volumes.
  • Bovine Serum Albumin is used as the standard in the protein determination according to the method described in Lowry et al., J. Biol. Chem., 193:265 (1951).
  • the volume of the suspended cell membranes is adjusted to give a tissue protein concentration of 1.0 mg/ml of suspension.
  • the prepared membrane suspension (10 times concentrated) is aliquoted in 1.0 ml volumes and stored at ⁇ 70° C. until used in subsequent binding experiments.
  • Binding experiments are performed in a 96 well microtiter plate format, in a total volume of 200 ⁇ l. To each well is added the following mixture: 80.0 ⁇ l of incubation buffer made in 50 mM Tris.HCl buffer (pH 7.4) containing 10.0 mM MgCl 2 and 0.5 mM EDTA and 20 ⁇ l of [ 3 H]-LSD (S.A., 86.0 Ci/mmol, available from Amersham Life Science), 3.0 nM.
  • the dissociation constant, K D of the [ 3 H] LSD at the human serotonin 5-HT6 receptor is 2.9 nM, as determined by saturation binding with increasing concentrations of [3H] LSD.
  • the reaction is initiated by the final addition of 100.0 ⁇ l of tissue suspension. Nonspecific binding is measured in the presence of 10.0 ⁇ M methiothepin.
  • the test compounds are added in 20.0 ⁇ l volume.
  • the reaction is allowed to proceed in the dark for 120 min at room temperature, at which time, the bound ligand-receptor complex is filtered off on a 96 well unifilter with a Packard Filtermate® 196 Harvester.
  • the bound complex caught on the filter disk is allowed to air dry and the radioactivity is measured in a Packard TopCount® equipped with six photomultiplier detectors, after the addition of 40.0 ⁇ l Microscint®-20 scintillant to each shallow well.
  • the unifilter plate is heat-sealed and counted in a PackardTopCount® with a tritium efficiency of 31.0%.
  • Specific binding to the 5-HT6 receptor is defined as the total radioactivity bound less the amount bound in the presence of 10.0 ⁇ M unlabeled methiothepin. Binding in the presence of varying concentrations of test compound is expressed as a percentage of specific binding in the absence of test compound. The results are plotted as log % bound versus log concentration of test compound. Nonlinear regression analysis of data points with a computer assisted program Prism® yielded both the IC 50 and the K i values of test compounds with 95% confidence limits.
  • K i IC 50 /(1 +L/K D ) where L is the concentration of the radioactive ligand used and K D is the dissociation constant of the ligand for the receptor, both expressed in nM.
  • the compounds of the present invention have a high degree of affinity for the 5-HT6 receptor.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor.
Figure US20050065185A1-20050324-C00001

Description

  • This application claims priority from copending application Ser. No. 60/285644, filed on Apr. 20, 2001, the entire disclosure of which is hereby incorporated by reference.
    • BACKGROUND OF THE INVENTION
  • Various central nervous system disorders such as anxiety, depression, motor disorders, etc., are believed to involve a disturbance of the neurotransmitter 5-hydroxytryptamine (5-HT) or serotonin. Serotonin is localized in the central and peripheral nervous systems and is known to affect many types of conditions including psychiatric disorders, motor activity, feeding behavior, sexual activity, and neuroendocrine regulation among others. The effects of serotonin are regulated by the various 5-HT receptor subtypes. Known 5-HT receptors include the 5-HT1 family (e.g. 5-HT1A), the 5-HT2 family (e.g. 5-HT2A), 5-HT3, 5-HT4, 5-HT5, 5-HT6 and 5-HT7 subtypes.
  • The recently identified human 5-hydroxytryptamine-6 (5-HT6) receptor subtype has been cloned, and the extensive distribution of its mRNA has been reported. Highest levels of 5-HT6 receptor mRNA have been observed in the olfactory tubercle, the striatum, nucleus accumbens, dentate gyrus and CA1, CA2 and CA3 regions of the hippocampus. Lower levels of 5-HT6 receptor mRNA were seen in the granular layer of the cerebellum, several diencephalic nuclei, amygdala and in the cortex. Northern blots have revealed that 5-HT6 receptor mRNA appears to be exclusively present in the brain, with little evidence for its presence in peripheral tissues. The high affinity of a number of antipsychotic agents for the 5-HT6 receptor, in addition to its mRNA localization in striatum, olfactory tubercle and nucleus accumbens suggests that some of the clinical actions of these compounds may be mediated through this receptor. Therefore, 5-HT6 receptor ligands are believed to be of potential use in the treatment of certain CNS disorders such as anxiety, depression, epilepsy, obsessive compulsive disorders, attention deficit disorder, migraine, cognitive memory enhancement (e.g. for the treatment of Alzheimer's disease), sleep disorders, feeding disorders (e.g. anorexia and bulimia), panic attacks, withdrawal from drug abuse (e.g. cocaine, ethanol, nicotine and benzodiazepines), schizophrenia, or the like; or in the treatment of certain gastrointestinal disorders such as irritable bowel syndrome.
  • Therefore, it is an object of this invention to provide compounds which are useful as therapeutic agents in the treatment of a variety of central nervous system disorders related to or affected by the 5-HT6 receptor.
  • It is another object of this invention to provide therapeutic methods and pharmaceutical compositions useful for the treatment of central nervous system disorders related to or affected by the 5-HT6 receptor.
  • It is a feature of this invention that the compounds provided may also be used to further study and elucidate the 5-HT6 receptor.
  • These and other objects and features of the invention will become more apparent by the detailed description set forth hereinbelow.
    • SUMMARY OF THE INVENTION
  • The present invention provides a compound of formula I
    Figure US20050065185A1-20050324-C00002
    wherein
      • W is SO2, CO, CONH, CSNH or (CH2)x;
      • X is O, SOy or NR13;
      • Y is CR14 or N;
      • Z is CR15 or N with the proviso that when Y is N then Z must be CR15;
      • m and x are each independently 0 or an integer of 1, 2 or 3;
      • n and p are each independently an integer of 1, 2 or 3;
      • R1 is halogen, CN, OR16, CO2R17, CONR18R19, CNR20NR21R22, SO2NR23R24, SOwR25, or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, phenyl or heteroaryl group each optionally substituted;
      • R2, R3, R5, R6, R7, R8, R9, R10 and R11 are each independently H or an optionally substituted C1-C6alkyl group;
      • R4 is H, CNR26NR27R28 or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
      • R12 is an optionally substituted C1-C6alkyl, aryl or heteroaryl group;
      • y and w are each 0 or an integer of 1 or 2;
      • R13 is H or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
      • R14 and R15 are each independently H, halogen or a C1-C6alkyl, aryl, heteroaryl or C1-C6alkoxy group each optionally substituted;
      • R16 is H, COR29 or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, aryl or heteroaryl group each optionally substituted;
      • R17 and R29 are each independently H or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
      • R18, R19, R20, R21, R22, R26, R27 and R28 are each independently H or an optionally substituted C1-C6alkyl group;
      • R23 and R24 are each independently H or a C1-C6alkyl, aryl or heteroaryl group each optionally substituted; and
      • R25 is an optionally substituted C1-C6alkyl, aryl, or heteroaryl group; or
        the stereoisomers thereof or the pharmaceutically acceptable salts thereof.
  • The present invention also provides methods and compositions useful for the therapeutic treatment of central nervous system disorders related to or affected by the 5-HT6 receptor.
  • The present invention further provides a method for the preparation of compounds of formula I and a compound useful therefor.
    • DETAILED DESCRIPTION OF THE INVENTION
  • The 5-hydroxytryptamine-6 (5-HT6) receptor is one of the most recent receptors to be identified by molecular cloning. Its ability to bind a wide range of therapeutic compounds used in psychiatry, coupled with its intriguing distribution in the brain has stimulated significant interest in new compounds which are capable of interacting with or affecting said receptor. At present, there are no known fully selective agonists. Significant efforts are being made to understand the possible role of the 5-HT6 receptor in psychiatry, cognitive dysfunction, motor function and control, memory, mood and the like. To that end, compounds which demonstrate a binding affinity for the 5-HT6 receptor are earnestly sought both as an aid in the study of the 5-HT6 receptor and as potential therapeutic agents in the treatment of central nervous system disorders.
  • Surprisingly, it has now been found that heterocyclylalkoxy-, -thioxy- or -aminobenzazole derivatives of formula I demonstrate 5-HT6 affinity. Advantageously, said benzazole derivatives may be used as effective therapeutic agents for the treatment of central nervous system (CNS) disorders associated with or affected by the 5-HT6 receptor. Accordingly, the present invention provides heterocyclylalkoxy-, -alkylthio- or -alkylaminobenzazole derivatives of formula I
    Figure US20050065185A1-20050324-C00003
    wherein
      • W is SO2, CO, CONH, CSNH or (CH2)x;
      • X is O, SOy or NR13;
      • Y is CR14 or N;
      • Z is CR15 or N with the proviso that when Y is N then Z must be CR15;
      • m and x are each independently 0 or an integer of 1, 2 or 3;
      • n and p are each independently an integer of 1, 2 or 3;
      • R1 is halogen, CN, OR16, CO2R17, CONR18R19, CNR20NR21R22, SO2NR23R24, SOwR25, or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, phenyl or heteroaryl group each optionally substituted;
      • R2, R3, R5, R6, R7, R8, R9, R10 and R11 are each independently H or an optionally substituted C1-C6alkyl group;
      • R4 is H, CNR26NR27R28, or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
      • R12 is an optionally substituted C1-C6alkyl, aryl or heteroaryl group;
      • y and w are each 0 or an integer of 1 or 2;
      • R13 is H or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
      • R14 and R15 are each independently H, halogen or a C1-C6alkyl, aryl, heteroaryl or C1-C6alkoxy group each optionally substituted;
      • R16 is H, COR29 or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, aryl or heteroaryl group each optionally substituted;
      • R17 and R29 are each independently H or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
      • R18, R19, R20, R21, R26, R27 and R28 are each independently H or an optionally substituted C1-C6alkyl group;
      • R23 and R24 are each independently H or a C1-C6alkyl, aryl or heteroaryl group each optionally substituted; and
      • R25 is an optionally substituted C1-C6alkyl, aryl, or heteroaryl group; or
        the stereoisomers thereof or the pharmaceutically acceptable salts thereof.
  • As used in the specification and claims, the term halogen designates Br, Cl, I or F and the term cycloheteroalkyl designates a C5-C7cycloalkyl ring system containing 1 or 2 heteroatoms, which may be the same or different, selected from N, O or S and optionally containing one double bond. Exemplary of the cycloheteroalkyl ring systems included in the term as designated herein are the following rings wherein X1 is NR, O or S.
    Figure US20050065185A1-20050324-C00004
  • Similarly, as used in the specification and claims, the term heteroaryl designates a 5- to 10-membered aromatic ring system containing 1 or 2 heteroatoms, which may be the same or different, selected from N, O or S. Such heteroaryl ring systems include pyrrolyl, azolyl, oxazolyl, thiazolyl, imidazolyl, furyl, thienyl, quinolinyl, isoquinolinyl, indolinyl, benzothienyl, benzofuranyl, benzisoxazolyl or the like. The term haloalkyl as used herein designates a CnH2n+1 group having from one to 2n+1 halogen atoms which may be the same or different and the term haloalkoxy as used herein designates an OCnH2n+1 group having from one to 2n+1 halogen atoms which may be the same or different.
  • In the specification and claims, when the terms C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C7cycloalkyl, cycloheteroalkyl, phenyl or heteroaryl are designated as being optionally substituted, the substituent groups which are optionally present may be one or more of those customarily employed in the development of pharmaceutical compounds or the modification of such compounds to influence their structure/activity, persistence, absorption, stability or other beneficial property. Specific examples of such substituents include halogen atoms, nitro, cyano, thiocyanato, cyanato, hydroxyl, alkyl, haloalkyl, alkoxy, haloalkoxy, amino, alkylamino, dialkylamino, formyl, alkoxycarbonyl, carboxyl, alkanoyl, alkylthio, alkylsuphinyl, alkylsulphonyl, carbamoyl, alkylamido, phenyl, phenoxy, benzyl, benzyloxy, heterocyclyl or cycloalkyl groups, preferably halogen atoms or lower alkyl groups. Typically, 0-3 substituents may be present. When any of the foregoing substituents represents or contains an alkyl substituent group, this may be linear or branched and may contain up to 12, preferably up to 6, more preferably up to 4 carbon atoms.
  • Pharmaceutically acceptable salts may be any acid addition salt formed by a compound of formula I and a pharmaceutically acceptable acid such as phosphoric, sulfuric, hydrochloric, hydrobromic, citric, maleic, malonic, mandelic, succinic, fumaric, acetic, lactic, nitric, sulfonic, p-toluene sulfonic, methane sulfonic acid or the like.
  • Compounds of the invention may exist as one or more stereoisomers. The various stereoisomers include enantiomers, diastereomers, atropisomers and geometric isomers. One skilled in the art will appreciate that one stereoisomer may be more active or may exhibit beneficial effects when enriched relative to the other stereoisomer(s) or when separated from the other stereoisomer(s). Additionally, the skilled artisan knows how to separate, enrich or selectively prepare said stereoisomers. Accordingly, the present invention comprises compounds of Formula I, the stereoisomers thereof and the pharmaceutically acceptable salts thereof. The compounds of the invention may be present as a mixture of stereoisomers, individual stereoisomers, or as an opticaly active form.
  • Preferred compounds of the invention are those compounds of formula I wherein W is SO2 or CO. Also preferred are those compounds of formula I wherein X is O. Another group of preferred compounds of the invention are those compounds of formula I wherein Y is CR14.
  • Further preferred compounds of the invention are those compounds of formula I wherein R12 is an aryl or heteroaryl group each optionally substituted; and n is 1.
  • More preferred compounds of the invention are those compounds of formula I wherein W is SO2; X is O; and n is 1. Another group of more preferred compounds of the invention are those compounds of formula I wherein W is SO2; X is O; Y is CR14; n is 1; and p is 1.
  • Among the preferred compounds of the invention are:
      • 1-(phenylsulfonyl)-4-[(2S)-pyrrolidin-2-ylmethoxy]-1H-indole;
      • 1-[(5-chlorothien-2-yl)sulfonyl]-4-[(2S)-pyrrolidin-2-ylmethoxy]-1H-indole;
      • 1-[(2-fluorophenyl)sulfonyl)-4-[(2S)-pyrrolidin-2-ylmethoxy]-1H-indole;
      • 1-[(3-fluorophenyl)sulfonyl)-4-[(2S)-pyrrolidin-2-ylmethoxy]-1H-indole;
      • 1-[(4-fluorophenyl)sulfonyl)-4-[(2S)-pyrrolidin-2-ylmethoxy]-1H-indole;
      • 1-[(3,4-dimethoxyphenyl)sulfonyl)-4-[(2S)-pyrrolidin-2-ylmethoxy]-1H-indole;
      • 4-({4-[2S)-pyrrolidin-2-ylmethoxy]-1H-indole-1-yl}sulfonyl)aniline;
      • 1-(phenylsulfonyl)-4-[(2R)-pyrrolidin-2-ylmethoxy]-1H-indole;
      • 1-(phenylsulfonyl)-4-[(2S)-pyrrolidin-2-ylmethoxy]-1H-indazole;
      • 8-({4-[(2S)-pyrrolidin-2-ylmethoxy]-1H-indazol-1-yl}sulfonyl)quinoline;
      • 1-[(2-chlorophenyl)sulfonyl]-4-[(2S)-pyrrolidin-2-ylmethoxy]-1H-indazole;
      • 1-[(2-fluorophenyl)sulfonyl]-4-[(2S)-pyrrolidin-2-ylmethoxy]-1H-indazole;
      • 1-[(5-chlorothien-2-yl)sulfonyl]-4-[(2S)-pyrrolidin-2-ylmethoxy]-1H-indazole;
      • 4-({4-[(2S)-pyrrolidin-2-ylmethoxy}-1H-indazol-1-yl}sulfonyl)aniline;
      • 2-chloro-4-({4-[(2S)-pyrrolidin-2-ylmethoxy]-1H-indazol-1-yl}sulfonyl)aniline;
      • 1-(phenylsulfonyl)-4-(piperidin-2-ylmethoxy)-1H-indole;
      • 4-{[4-(piperidin-2-ylmethoxy)-1H-indol-1-yl]sulfonyl}aniline;
      • 1-[(2-fluorophenyl)sulfonyl]-4-(piperidin-2-ylmethoxy)-1H-indole;
      • 1-[(5-chlorothien-2-yl)sulfonyl]-4-(piperidin-2-ylmethoxy)-1H-indole;
      • 1-[(3-fluorophenyl)sulfonyl]-4-(piperidin-2-ylmethoxy)-1H-indole;
      • 1-[(2-fluorophenyl)sulfonyl]-4-(piperidin-2-ylmethoxy)-1H-indazole;
      • 1-[(2-chlorophenyl)sulfonyl]-4-(piperidin-2-ylmethoxy)-1H-indazole;
      • 1-[(5-chlorothien-2-yl)sulfonyl]-4-(piperidin-2-ylmethoxy)-1H-indazole;
      • 4-(azepan-2-ylmethoxy)-1-(phenylsulfonyl)-1H-indole;
      • 4-{[4-(azepan-2-ylmethoxy)-1H-indol-1-yl]sulfonyl}aniline;
      • 4-(azepan-2-ylmethoxy)-1-[(2-fluorophenyl)sulfonyl]-1H-indole;
      • 4-(azepan-2-ylmethoxy)-1-[(5-chlorothien-2-yl)sulfonyl]-1H-indole;
      • 4-(azepan-2-ylmethoxy)-1-[(3-fluorophenyl)sulfonyl]-1H-indole;
      • 4-(azepan-2-ylmethoxy)-1-[(2-fluorophenyl)sulfonyl]-1H-indazole;
      • 4-(azepan-2-ylmethoxy)-1-[(2-chlorophenyl)sulfonyl]-1H-indazole;
      • 4-(azepan-2-ylmethoxy)-1-[(5-chlorothien-2-yl)sulfonyl]-1H-indazole;
      • 1-(phenylsulfonyl)-5-(pyrrolidin-2-ylmethoxy)-1H-indole;
      • 1-(phenylsulfonyl)-6-(pyrrolidin-2-ylmethoxy)-1H-indole;
      • 1-(phenylsulfonyl)-5-(pyrrolidin-2-ylmethoxy)-1H-indazole;
      • 1-(phenylsulfonyl)-6-(pyrrolidin-2-ylmethoxy)-1H-indazole; or
        the stereoisomers thereof or the pharmaceutically acceptable salts thereof.
  • Compounds of the invention may be prepared using conventional synthetic methods and, if required, standard separation and isolation techniques. For example, compounds of formula I wherein W is SO2; X is O; Y is CR13; Z is CR14; and R4 and R11 are H (Ia) may be prepared by reacting an hydroxyindole of formula II with an N-protected-2-methoxyheterocycle of formula III in the presence of triphenylphosphine and diethyl azodicarboxylate to give the corresponding indol-4-yloxyalkylheterocycle of formula IV. Subsequent sulfonylation and deprotection of the formula IV compound gives the desired formula Ia product. The reaction sequence is illustrated in flow diagram I wherein P represents a protecting group.
    Figure US20050065185A1-20050324-C00005
  • Commonly used protecting groups include t-butyl-carboxylate, benzyl, acetyl, benzyloxycarbonyl, or any conventional group known to protect a basic nitrogen in standard synthetic procedures.
  • Compounds of formula I wherein W is SO2; X is O; Y is CH; Z is N and R4 and R11 are H (Ib) may be prepared by reacting a nitromethylphenol of formula V with an N-protected-2-alkoxyheterocyclic compound of formula III in the presence of triphenylphosphine and diethyl azodicarboxylate to give the corresponding heterocyclylalkoxybenzene of formula VI, reducing the nitro group of the formula VI compound, for example via catalytic hydrogenation, to give the amine of formula VII and reacting the formula VII amine with isoamylnitrite in the presence of potassium acetate and acetic anhydride to give the heterocyclyalkoxyindazole of formula VIII. Sulfonylation and deprotection of said formula VIII compound gives the desired compound of formula Ib wherein R4 is H. Subsequent reaction of the formula Ib compound with a suitable alkylating reagent such as an alkyl or aralkyl halide, R4-Hal, gives those compounds of formula Ib′ wherein R4 is other than H. The reaction sequence is shown in flow diagram II wherein P is a protecting group and Hal is Cl, Br or I.
    Figure US20050065185A1-20050324-C00006
  • Compounds of formula I wherein W is SO2; X is NH; Y is CH; Z is N; and R4 and R11 are H (Ic) may be prepared by the reductive amination of an N-protected carbonylalkylheterocyclic compound of formula X with a nitromethylaniline compound of formula IX to give the compound of formula XI, reducing the nitro group to give the amine of formula XII and reacting the formula XII amine with isoamylnitrite in the presence of potassium acetate and acetic anhydride to give the heterocyclylalkylamino-indazole of formula XIII. Subsequent sulfonylation and deprotection as described hereinabove give the desired compound of formula Ic. The reaction sequence is shown in flow diagram III.
    Figure US20050065185A1-20050324-C00007
  • Similarly, compounds of formula I wherein W is SO2; X is NH; Y is CR13; Z is CR14; and R4 and R11 are H (Id) may be prepared by the reductive amination of the formula X carboxyaldehyde with an aminoindole of formula XIV to give the compound of formula XV. Subsequent sulfonylation and deprotection gives the desired product of formula Id. The reaction sequence is shown in flow diagram IV.
    Figure US20050065185A1-20050324-C00008
  • Compounds of formula I wherein X is S and W is SO2 may be prepared by employing the appropriate indolylthiol or thiophenol and utilizing the reactions shown in flow diagrams I and II, respectively.
  • Compounds of formula I wherein W is CO may be prepared by reacting the benzazole precursor, for example a compound of formula IV, VIII, XIII or XV with the appropriate isocyanate, carbonyl halide or carbamoyl halide in the presence of a base. Similarly, compounds of formula I wherein W is (CH2)x and x is an integer of 1, 2 or 3 may be prepared by reacting the appropriately substituted alkylhalide with a compound of formula IV, VIII, XIII or XV in the presence of a base. Compounds of formula I wherein W is (CH2)x and x is 0 may be prepared via a palladium-catalyzed N-arylation such as that descrited by D. W. Old et al, Organic Letters, 2000 (2), pp 1403-1406. Using these and other conventional methods, compounds of formula I may be prepared from readily available starting materials.
  • Advantageously, the present invention provides a compound of formula XVI
    Figure US20050065185A1-20050324-C00009
    wherein X, Y, Z, m, n, p, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 are as defined for formula I. Compounds of formula XVI are useful in the preparation of the therapeutic agents of formula I described hereinabove. Accordingly, the present invention also provides a method for the preparation of a compound of formula I wherein W is SO2 (Ie) which comprises reacting a formula XVI compound with a sulfonyl chloride, R12SO2Cl, wherein R12 is as defined for formula I in the presence of a base optionally in the presence of a solvent. The reaction is shown in flow diagram V.
    Figure US20050065185A1-20050324-C00010
  • Bases suitable for use in the method of invention are strong bases such as NaH, KOt-Bu, or any conventional base capable of removing a proton from a basic indole or benzazole nitrogen-atom.
  • Advantageously, the inventive compound of formula I may be utilized in the treatment of central nervous system disorders relating to or affected by the 5-HT6 receptor such as motor, mood, psychiatric, cognitive, neurodegenerative, or the like disorders, for example, Alzheimer's disease, Parkinson's disease, attention deficit disorder, anxiety, epilepsy, depression, obsessive compulsive disorder, migraine, sleep disorders, feeding disorders (such as anorexia or bulimia), schizophrenia, memory loss, disorders associated with withdrawl from drug abuse, or the like or certain gastrointestinal disorders such as irritable bowel syndrome. Accordingly, the present invention provides a method for the treatment of a disorder of the central nervous system (CNS) related to or affected by the 5-HT6 receptor in a patient in need thereof which comprises providing said patient a therapeutically effective amount of a compound of formula I as described hereinabove. The compounds may be provided by oral or parenteral administration or in any common manner known to be an effective administration of a therapeutic agent to a patient in need thereof.
  • The therapeutically effective amount provided in the treatment of a specific CNS disorder may vary according to the specific condition(s) being treated, the size, age and response pattern of the patient, the severity of the disorder, the judgment of the attending physician and the like. In general, effective amounts for daily oral administration may be about 0.01 to 1,000 mg/kg, preferably about 0.5 to 500 mg/kg and effective amounts for parenteral administration may be about 0.1 to 100 mg/kg, preferably about 0.5 to 50 mg/kg.
  • In actual practice, the compounds of the invention are provided by administering the compound or a precursor thereof in a solid or liquid form, either neat or in combination with one or more conventional pharmaceutical carriers or excipients. Accordingly, the present invention provides a pharmaceutical composition which comprises a pharmaceutically acceptable carrier and an effective amount of a compound of formula I as described hereinabove.
  • Solid carriers suitable for use in the composition of the invention include one or more substances which may also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aides, binders, tablet-disintegrating agents or encapsulating materials. In powders, the carrier may be a finely divided solid which is in admixture with a finely divided compound of formula I. In tablets, the formula I compound may be mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired. Said powders and tablets may contain up to 99% by weight of the formula I compound. Solid carriers suitable for use in the composition of the invention include calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidine, low melting waxes and ion exchange resins.
  • Any pharmaceutically acceptable liquid carrier suitable for preparing solutions, suspensions, emulsions, syrups and elixirs may be employed in the composition of the invention. Compounds of formula I may be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, or a pharmaceutically acceptable oil or fat, or a mixture thereof. Said liquid composition may contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, coloring agents, viscosity regulators, stabilizers, osmo-regulators, or the like. Examples of liquid carriers suitable for oral and parenteral administration include water (particularly containing additives as above, e.g., cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols, e.g., glycols) or their derivatives, or oils (e.g., fractionated coconut oil and arachis oil). For parenteral administration the carrier may also be an oily ester such as ethyl oleate or isopropyl myristate.
  • Compositions of the invention which are sterile solutions or suspensions are suitable for intramuscular, intraperitoneal or subcutaneous injection. Sterile solutions may also be administered intravenously. Inventive compositions suitable for oral administration may be in either liquid or solid composition form.
  • For a more clear understanding, and in order to illustrate the invention more clearly, specific examples thereof are set forth hereinbelow. The following examples are merely illustrative and are not to be understood as limiting the scope and underlying principles of the invention in any way.
  • Unless otherwise stated, all parts are parts by weight. The term NMR designates nuclear magnetic resonance. The terms THF and EtOAc designate tetrahydrofuran and ethyl acetate, respectively.
    • EXAMPLE 1 Preparation of t-Butyl (2S)-2-[(1H-indol-4-yloxy)methyl]-1-pyrrolidinecarboxylate
  • Figure US20050065185A1-20050324-C00011
  • A solution of 4-hydroxyindole (1.33 g, 10.0 mmol), (S)-(−)-1-t-butoxycarbonyl)-2-pyrrolidine methanol (4.02 g, 20.0 mmol) and triphenylphosphine (5.3 g, 20.0 mmol) in THF is treated with diethyl azodicarboxylate (3.2 mL, 20.0 mmol) under nitrogen at room temperature, stirred for 2 h at room temperature and concentrated in vacuo. The resultant residue is purified by flash chromatography (silica gel, EtOAc/hexane: 20/80) to give the title compound as a white solid, 1.5 g, mp 40-41° C., identified by NMR and mass spectral analyses.
    • EXAMPLE 2 Preparation of t-Butyl (2S)-2-({[1-(Phenylsulfonyl)-1H-indol-4-yl]oxy}methyl)-1-pyrrolidinecarboxylate
  • Figure US20050065185A1-20050324-C00012
  • A stirred solution of t-butyl (2S)-2-[(1H-indol-4-yloxy)methyl]-1-pyrrolidinecarboxylate (1.23 g, 3.89 mmol) in THF is treated with sodium hydride (0.17 g, 60% in mineral oil, 4.28 mmol) under nitrogen at room temperature, stirred for 30 minutes, treated with benzenesulfonyl chloride (0.55 mL, 4.28 mmol), stirred at room temperature for 22 h, quenched with ice-water and diluted with EtOAc. The organic phase is separated, washed sequentially with water and brine, dried over MgSO4 and concentrated in vacuo. The resultant residue is purified by flash chromatography (siliga gel, EtOAc/hexanes, 2/8) to afford the title compound as an off-white foam, 1.21 g, mp 48-50° C., identified by NMR and mass spectral analyses.
    • EXAMPLE 3 Preparation of 1-(Phenylsulfonyl)-4-[(2S)-pyrrolidin-2-ylmethoxy]-1H-indole hydrochloride
  • Figure US20050065185A1-20050324-C00013
  • A solution of t-butyl (2S)-2-({[1-phenylsulfonyl)-1H-indol-4-yl]oxy}methyl)-1-pyrrolidinecarboxylate (1.06 g, 2.32 mmol) in methanol and HCl (11.6 mL 1M in ether) is heated at 60° C. under nitrogen for 2 h, cooled to room temperature and concentrated in vacuo. The resultant residue is treated with EtOAc and filtered. The filtercake is dried in vacuo to give the title compound as an off-white solid, 0.89 g, mp 194-196° C., identified by NMR and mass spectral analyses.
    • EXAMPLES 4-9 Preparation of 1-(Arylsulfonyl)-4-[(2S)-pyrrolidin-2-ylmethoxy]-1H-indole Hydrochloride
  • Figure US20050065185A1-20050324-C00014
  • Using essentially the same procedure described in Examples 2 and 3 hereinabove and employing potassium t-butoxide and the appropriate arylsulfonyl chloride, the compounds shown in Table I are obtained and identified by NMR and mass spectral analyses.
    TABLE I
    Figure US20050065185A1-20050324-C00015
    Example mp
    No. R12 X ° C.
    4 5-chlorothien-2-yl 1 204-206
    5 2-fluorophenyl 1 153-155
    6 3-fluorophenyl 1 160-162
    7 4-fluorophenyl 1 258 (dec)
    8 3,4-dimethoxyphenyl 1 115 (dec)
    9 4-aminophenyl 2 150 (dec)
    • EXAMPLE 10 Preparation of t-Butyl (2R)-2-[(1H-indol-4-yloxy)methyl]-pyrrolidine-1-carboxylate
  • Figure US20050065185A1-20050324-C00016
  • A stirred solution of 4-hydroxyindole (1.33 g, 10.0 mmol), (R)-(+)-1-(t-butoxycarbonyl)-2-pyrrolidinemethanol (4.02 g, 20.0 mmol) and triphenylphosphine (5.3 g, 20.0 mmol) in THF is treated with diethyl azodicarboxylate (3.2 mL, 20 mmol), stirred for 3 h at room temperature and concentrated in vacuo. The resultant residue is treated with EtOAc and filtered through a pad of silica gel. The filtrate is concentrated to give a residue which is purified by chromatography (silica gel, EtOAc:hexanes, 15:80) to afford the title compound as a white solid, 1.08 g, mp 146-147° C.; identified by NMR and mass spectral analyses.
    • EXAMPLE 11 Preparation of 1-(Phenylsulfonyl)-4-[(2R)-]pyrrolidin-2-ylmethoxy]-1H-indole hydrochloride
  • Figure US20050065185A1-20050324-C00017
  • A solution of t-butyl (2R)-2-[(1H-indol-4-yloxy)methyl]pyrrolidine-1-carboxylate (0.316 g, 1.0 mmol) in THF is treated with potassium t-butoxide (1.5 mL, 1.5 mmol, 1M in THF) at room temperature, stirred for 3 min, treated with benzenesulfonyl chloride (0.264 g, 1.5 mmol), stirred for 6 h under nitrogen at room temperature, quenched with 1N aqueous HCl and water and diluted with EtOAc. The organic phase is separated, washed sequentially with water and brine, dried over MgSO4 and concentrated in vacuo. The resultant residue is treated with HCl (1.5 mL, 1N in Et2O), heated at reflux temperature for 3 h, cooled to room temperature and filtered. The filtercake is air-dried to afford the title compound as an off-white solid, 0.24 g, mp 204-206° C., identified by NMR and mass spectral analyses.
    • EXAMPLE 12 Preparation of t-Butyl (2S)-2-[(2-methyl-3-nitrophenoxy)methyl]pyrrolidine-1-carboxylate
  • Figure US20050065185A1-20050324-C00018
  • A stirred solution of 2-methyl-3-nitrophenol (3.80 g, 24.84 mmol), (S)-(−)-1-tert-butoxycarbonyl)-2-pyrrolidinemethanol (5.0 g, 24.8 mmol) and triphenylphosphine (6.5 g, 24.8 mmol) in THF is treated with diethylazodicarboxylate (4.3 g, 24.8 mmol), stirred for 3 h at room temperature and concentrated in vacuo. The resultant residue is mixed with ether, stored at 0° C. overnight and filtered. The filtrate is concentrated in vacuo to give a residue which is purified by chromatography (silica gel, EtOAc:hexanes, 20:80) to afford the title compound as a light yellow semisolid, 7.73 g, (91% yield), identified by NMR and mass spectral analyses.
    • EXAMPLE 13 Preparation of t-Butyl (2S)-2-[(3-amino-2-methylphenoxy)methyl]pyrrolidine-1-carboxylate
  • Figure US20050065185A1-20050324-C00019
  • A solution of t-butyl (2S)-2-[(2-methyl-3-nitrophenoxy)methyl]pyrrolidine-1-carboxylate (7.63 g, 21.9 mmol) and 10% Pd/C (0.38 g) in ethanol is hydrogenated (50 psi) at room temperature for 4 h and filtered. The filtrate is concentrated in vacuo to afford the title compound as an off-white solid, 6.66 g, mp 110° C., identified by NMR and mass spectral analyses.
    • EXAMPLE 14 Preparation of t-Butyl (2S)-2-[(1H-indazol-4-yloxy)methyl]pyrrolidine-1-carboxylate
  • Figure US20050065185A1-20050324-C00020
  • A solution of t-butyl (2S)-2-[(3-amino-2-methylphenoxy) methyl]pyrrolidine-1-carboxylate (5.00 g, 16.33 mmol), potassium acetate (1.92 g, 19.6 mmol) and acetic anhydride (4.9 mL, 52.3 mmol) in benzene is treated dropwise with isoamylnitrite (4.3 mL, 32.7 mmol), heated at reflux temperature overnight, cooled to room temperature and filtered. The filtercake is washed with benzene. The filtrates are combined and concentrated in vacuo to give a yellow oil residue. The residue is purified by chromatography (silica gel, EtOAc:hexanes, 15:85). The purified oil (5.05 g) is dissolved in ethanol, treated with 40% aqueous NaOH, heated at reflux temperature for 45 min, cooled in an ice-water bath, neutralized to pH 8 with concentrated HCl and concentrated in vacuo to remove the ethanol. The resultant aqueous residue is extracted with EtOAc. The combined extracts are washed sequentially with water and brine, dried over MgSO4 and concentrated in vacuo to give a yellow oil. This oil is purified by chromatography (silica gel, EtOAc:hexanes, 30:70) to give the title product as an off-white solid, 3.52 g, mp 125° C., identified by NMR and mass spectral analyses.
    • EXAMPLE 15 Preparation of 1-(Phenylsulfonyl)-4-[(2S)-pyrrolidin-2-ylmethoxy]-1H-indazole trifluoroacetic acid salt
  • Figure US20050065185A1-20050324-C00021
  • A solution of t-butyl (2S)-2-[(1H-indazol-4-yloxy)methyl]pyrrolidine-1-carboxylate (0.317 g, 1.0 mmol) in dimethylformamide is treated with sodium hydride (0.08 g, 2.0 mmol, 60% in mineral oil) at room temperature, stirred for 10 min, treated with benzenesulfonyl chloride (0.264 g, 1.5 mmol), stirred for 18 h under nitrogen at room temperature, quenched with water and diluted with ether. The organic phase is separated, washed sequentially with water and brine, dried over MgSO4 and concentrated in vacuo to give a white foam residue. The residue is purified by chromatography (silica gel, EtOAc:hexanes, 15:85) to give a white solid. This solid is dissolved in trifluoroacetic acid at 0° C., stirred at room temperature for 90 min and concentrated in vacuo. The resultant residue is triturated under ether to afford the title compound as a white solid, 300 mg, mp 218-219° C., identified by NMR and mass spectral analyses.
    • EXAMPLES 16-21 Preparation of 1-Arylsulfonyl-4[(2S)-pyrrolidinylmethoxy]1H-indazole Hydrochloride
  • Figure US20050065185A1-20050324-C00022
  • Using essentially the same procedure described in Example 15 hereinabove and employing the appropriate arysulfonyl chloride and anhydrous HCl, the compounds in Table II are obtained and identified by NMR and mass spectral analyses.
    TABLE II
    Figure US20050065185A1-20050324-C00023
    Example mp
    No. R12 X ° C.
    16 8-quinolinyl 0 217-218
    17 2-chlorophenyl 1 >255 (dec)
    18 2-fluorophenyl 1 145-148
    19 5-chlorothien-2-yl 1 195
    20 4-aminophenyl 2 150-155
    21 4-amino-3-chlorophenyl 2   220 (dec)
    • EXAMPLE 22 Comparative Evaluation of 5-HT6 Binding Affinity of Test Compounds
  • The affinity of test compounds for the serotonin 5-HT6 receptor is evaluated in the following manner. Cultured Hela cells expressing human cloned 5-HT6 receptors are harvested and centrifuged at low speed (1,000×g) for 10.0 min to remove the culture media. The harvested cells are suspended in half volume of fresh physiological phosphate buffered saline solution and recentrifuged at the same speed. This operation is repeated. The collected cells are then homogenized in ten volumes of 50 mM Tris.HCl (pH 7.4) and 0.5 mM EDTA. The homogenate is centrifuged at 40,000×g for 30.0 min and the precipitate is collected. The obtained pellet is resuspended in 10 volumes of Tris.HCl buffer and recentrifuged at the same speed. The final pellet is suspended in a small volume of Tris.HCl buffer and the tissue protein content is determined in aliquots of 10-25 μl volumes. Bovine Serum Albumin is used as the standard in the protein determination according to the method described in Lowry et al., J. Biol. Chem., 193:265 (1951). The volume of the suspended cell membranes is adjusted to give a tissue protein concentration of 1.0 mg/ml of suspension. The prepared membrane suspension (10 times concentrated) is aliquoted in 1.0 ml volumes and stored at −70° C. until used in subsequent binding experiments.
  • Binding experiments are performed in a 96 well microtiter plate format, in a total volume of 200 μl. To each well is added the following mixture: 80.0 μl of incubation buffer made in 50 mM Tris.HCl buffer (pH 7.4) containing 10.0 mM MgCl2 and 0.5 mM EDTA and 20 μl of [3H]-LSD (S.A., 86.0 Ci/mmol, available from Amersham Life Science), 3.0 nM. The dissociation constant, KD of the [3H] LSD at the human serotonin 5-HT6 receptor is 2.9 nM, as determined by saturation binding with increasing concentrations of [3H] LSD. The reaction is initiated by the final addition of 100.0 μl of tissue suspension. Nonspecific binding is measured in the presence of 10.0 μM methiothepin. The test compounds are added in 20.0 μl volume.
  • The reaction is allowed to proceed in the dark for 120 min at room temperature, at which time, the bound ligand-receptor complex is filtered off on a 96 well unifilter with a Packard Filtermate® 196 Harvester. The bound complex caught on the filter disk is allowed to air dry and the radioactivity is measured in a Packard TopCount® equipped with six photomultiplier detectors, after the addition of 40.0 μl Microscint®-20 scintillant to each shallow well. The unifilter plate is heat-sealed and counted in a PackardTopCount® with a tritium efficiency of 31.0%.
  • Specific binding to the 5-HT6 receptor is defined as the total radioactivity bound less the amount bound in the presence of 10.0 μM unlabeled methiothepin. Binding in the presence of varying concentrations of test compound is expressed as a percentage of specific binding in the absence of test compound. The results are plotted as log % bound versus log concentration of test compound. Nonlinear regression analysis of data points with a computer assisted program Prism® yielded both the IC50 and the Ki values of test compounds with 95% confidence limits. A linear regression line of data points is plotted, from which the IC50 value is determined and the Ki value is determined based upon the following equation:
    K i =IC 50/(1+L/K D)
    where L is the concentration of the radioactive ligand used and KD is the dissociation constant of the ligand for the receptor, both expressed in nM.
  • Using this assay, the following Ki values are determined and compared to those values obtained by representative compounds known to demonstrate binding to the 5-HT6 receptor. The data are shown in Table III, below.
    TABLE III
    5-HT6 Binding Ki
    (nM)
    Test Compound
    (Ex. No.)
    3 6.0
    4 7.0
    5 2.0
    6 8.0
    7 31.0
    8 95.0
    9 1.0
    11 106
    15 7.0
    16 85.0
    17 5.0
    18 8.0
    19 5.0
    20 9.0
    21 16.0
    Comparative Examples
    Clozapine 6.0
    Loxapine 41.4
    Bromocriptine 23 .0
    Methiothepin 8.3
    Mianserin 44.2
    Olanzepine 19.5
  • As can be seen from the results set forth above, the compounds of the present invention have a high degree of affinity for the 5-HT6 receptor.

Claims (23)

1. A compound of formula I
Figure US20050065185A1-20050324-C00024
wherein
W is SO2, CO, CONH, CSNH or (CH2)x;
X is O, SOy or NR13;
Y is CR14 or N;
Z is CR15 or N with the proviso that when Y is N then Z must be CR15;
m and x are each independently 0 or an integer of 1, 2 or 3;
n and p are each independently an integer of 1, 2 or 3 with the proviso that when p is an integer of 1 then one of Y and Z must be N;
R1 is halogen, CN, OR16, CO2R17, CONR18R19, CNR20NR21R22, SO2NR23R24, SOwR25, or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, phenyl or heteroaryl group each optionally substituted;
R2, R3, R5, R6, R7, R8, R9, R10 and R11 are each independently H or an optionally substituted C1-C6alkyl group;
R4 is H, CNR26NR27R28 or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
R12 is an optionally substituted C1-C6alkyl, aryl or heteroaryl group;
y and w are each 0 or an integer of 1 or 2;
R13 is H or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
R14 and R15 are each independently H, halogen or a C1-C6alkyl, aryl, heteroaryl or C1-C6alkoxy group each optionally substituted;
R16 is H, COR29 or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, aryl or heteroaryl group each optionally substituted;
R17 and R29 are each independently H or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
R18, R19, R20, R21, R22, R26, R27 and R28 are each independently H or an optionally substituted C1-C6alkyl group;
R23 and R24 are each independently H or a C1-C6alkyl, aryl or heteroaryl group each optionally substituted; and
R25 is an optionally substituted C1-C6alkyl, aryl, or heteroaryl group; or the stereoisomers thereof or the pharmaceutically acceptable salts thereof.
2. The compound according to claim 1 wherein W is SO2.
3. The compound according to claim 1 wherein X is O.
4. The compound according to claim 1 wherein Y is CR14.
5. The compound according to claim 1 wherein n is 1.
6. The compound according to claim 2 wherein R12 is an aryl or heteroaryl group each optionally substituted.
7. The compound according to claim 6 wherein X is O and n is 1.
8. The compound according to claim 7 wherein Y is CR14 and p is 1.
9. The compound according to claim 7 selected from the group consisting of
1-(phenylsulfonyl)-4-[(2S)-pyrrolidin-2-ylmethoxy]-1H-indazole;
8-({4-[(2S)-pyrrolidin-2-ylmethoxy]-1H-indazol-1-yl}sulfonyl)quinoline;
1-[(2-chlorophenyl)sulfonyl]-4-[(2S)-pyrrolidin-2-ylmethoxy]-1H-indazole;
1-[(2-fluorophenyl)sulfonyl]-4-[(2S)-pyrrolidin-2-ylmethoxy]-1H-indazole;
1-[(5-chlorothien-2-yl)sulfonyl]-4-[(2S)-pyrrolidin-2-ylmethoxy]-1H-indazole;
4-({4-[(2S)-pyrrolidin-2-ylmethoxy}-1H-indazol-1-yl}sulfonyl)aniline;
2-chloro-4-({4-[(2S)-pyrrolidin-2-ylmethoxy]-1H-indazol-1-yl}sulfonyl)aniline;
1-(phenylsulfonyl)-4-(piperidin-2-ylmethoxy)-1H-indole;
4-{[4-(piperidin-2-ylmethoxy)-1H-indol-1-yl]sulfonyl}aniline;
1-[(2-fluorophenyl)sulfonyl]-4-(piperidin-2-ylmethoxy)-1H-indole;
1-[(5-chlorothien-2-yl)sulfonyl]-4-(piperidin-2-ylmethoxy)-1H-indole;
1-[(3-fluorophenyl)sulfonyl]-4-(piperidin-2-ylmethoxy)-1H-indole;
1-[(2-fluorophenyl)sulfonyl]-4-(piperidin-2-ylmethoxy)-1H-indazole;
1-[(2-chlorophenyl)sulfonyl]-4-(piperidin-2-ylmethoxy)-1H-indazole;
1-[(5-chlorothien-2-yl)sulfonyl]-4-(piperidin-2-ylmethoxy)-1H-indazole;
4-(azepan-2-ylmethoxy)-1-(phenylsulfonyl)-1H-indole;
4-{[4-(azepan-2-ylmethoxy)-1H-indol-1-yl]sulfonyl}aniline;
4-(azepan-2-ylmethoxy)-1-[(2-fluorophenyl)sulfonyl]-1H-indole;
4-(azepan-2-ylmethoxy)-1-[(5-chlorothien-2-yl)sulfonyl]-1H-indole;
4-(azepan-2-ylmethoxy)-1-[(3-fluorophenyl)sulfonyl]-1H-indole;
4-(azepan-2-ylmethoxy)-1-[(2-fluorophenyl)sulfonyl]-1H-indazole;
4-(azepan-2-ylmethoxy)-1-[(2-chlorophenyl)sulfonyl]-1H-indazole;
4-(azepan-2-ylmethoxy)-1-[(5-chlorothien-2-yl)sulfonyl]-1H-indazole;
1-(phenylsulfonyl)-5-(pyrrolidin-2-ylmethoxy)-1H-indazole;
1-(phenylsulfonyl)-6-(pyrrolidin-2-ylmethoxy)-1H-indazole;
the stereoisomers thereof; and
the pharmaceutically acceptable salts thereof.
10. A method for the treatment of a disorder of the central nervous system related to or affected by the 5-HT6 receptor in a patient in need thereof which comprises providing to said patient a therapeutically effective amount of a compound of formula I
Figure US20050065185A1-20050324-C00025
wherein
W is SO2, CO, CONH, CSNH or (CH2)x;
X is O, SOy or NR13;
Y is CR14 or N;
Z is CR15 or N with the proviso that when Y is N then Z must be CR15;
m and x are each independently 0 or an integer of 1, 2 or 3;
n and p are each independently an integer of 1, 2 or 3;
R1 is halogen, CN, OR16, CO2R17, CONR18R19, CNR20NR21R22, SO2NR23R24, SOwR25, or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, phenyl or heteroaryl group each optionally substituted;
R2, R3, R5, R6, R7, R8, R9, R10 and R11 are each independently H or an optionally substituted C1-C6alkyl group;
R4 is H, CNR26NR27R28 or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
R12 is an optionally substituted C1-C6alkyl, aryl or heteroaryl group;
y and w are each 0 or an integer of 1 or 2;
R13 is H or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl aryl or heteroaryl group each optionally substituted;
R14 and R15 are each independently H, halogen or a C1-C6alkyl, aryl, heteroaryl or C1-C6alkoxy group each optionally substituted;
R16 is H, COR29 or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, aryl or heteroaryl group each optionally substituted;
R17 and R29 are each independently H or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
R18, R19, R20, R21, R22, R26, R27 and R28 are each independently H or an optionally substituted C1-C6alkyl group;
R23 and R24 are each independently H or a C1-C6alkyl, aryl or heteroaryl group each optionally substituted; and
R25 is an optionally substituted C1-C6alkyl, aryl, or heteroaryl group; or the stereoisomers thereof or the pharmaceutically acceptable salts thereof.
11. The method according to claim 10 wherein said disorder is a motor disorder, anxiety disorder or cognitive disorder.
12. The method according to claim 10 wherein said disorder is schizophrenia or depression.
13. The method according to claim 11 wherein said disorder is Alzheimer's disease or Parkinson's diease.
14. The method according to claim 11 wherein said disorder is attention deficit disorder.
15. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and an effective amount of a compound of formula I
Figure US20050065185A1-20050324-C00026
wherein
W is SO2, CO, CONH, CSNH or (CH2)x;
X is O, SOy or NR13;
Y is CR14 or N;
Z is CR15 or N with the proviso that when Y is N then Z must be CR15;
m and x are each independently 0 or an integer of 1, 2 or 3;
n and p are each independently an integer of 1, 2 or 3 with the proviso that when p is an integer of 1 then one of Y and Z must be N;
R1 is halogen, CN, OR16, CO2R17, CONR18R19, CNR20NR21R22, SO2NR23R24, SOwR25, or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, phenyl or heteroaryl group each optionally substituted;
R2, R3, R5, R6, R7, R8, R9, R10 and R11 are each independently H or an optionally substituted C1-C6alkyl group;
R4 is H, CNR26NR27R28 or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl; cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
R12 is an optionally substituted C1-C6alkyl, aryl or heteroaryl group;
y and w are each 0 or an integer of 1 or 2;
R13 is H or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
R14 and R15 are each independently H, halogen or a C1-C6alkyl, aryl, heteroaryl or C1-C6alkoxy group each optionally substituted;
R16 is H, COR29 or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, aryl or heteroaryl group each optionally substituted;
R17 and R29 are each independently H or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
R18, R19, R20, R21, R22, R26, R27 and R28 are each independently H or an optional substituted C1-C6alkyl group;
R23 and R24 are each independently H or a C1-C6alkyl, aryl or heteroaryl group each optionally substituted; and
R25 is an optionally substituted C1-C6alkyl, aryl, or heteroaryl group; or the stereoisomers thereof or the pharmaceutically acceptable salts thereof.
16. The composition according to claim 15 having a formula I compound wherein W is SO2.
17. The composition according to claim 16 having a formula I wherein X is O.
18. The composition according to claim 16 having a formula I compound wherein Y is CR14 and n is 1.
19. The composition according to claim 18 having a formula I compound selected from the group consisting of:
1-(phenylsulfonyl)-4-[(2S)-pyrrolidin-2-ylmethoxy]-1H-indazole;
8-({4-[(2S)-pyrrolidin-2-ylmethoxy]-1H-indazol-1-yl}sulfonyl)quinoline;
1-[(2-chlorophenyl)sulfonyl]-4-[(2S)-pyrrolidin-2-ylmethoxy]-1H-indazole;
1-[(2-fluorophenyl)sulfonyl]-4-[(2S)-pyrrolidin-2-ylmethoxy]-1H-indazole;
1-[(5-chlorothien-2-yl)sulfonyl]-4-[(2S)-pyrrolidin-2-ylmethoxy]-1H-indazole;
4-({4-[(2S)-pyrrolidin-2-ylmethoxy}-1H-indazol-1-yl}sulfonyl)aniline;
2-chloro-4-({4-[(2S)-pyrrolidin-2-ylmethoxy]-1H-indazol-1-yl}sulfonyl)aniline;
1-(phenylsulfonyl)-4-(piperidin-2-ylmethoxy)-1H-indole;
4-{[4-(piperidin-2-ylmethoxy)-1H-indol-1-yl]sulfonyl}aniline;
1-[(2-fluorophenyl)sulfonyl]-4-(piperidin-2-ylmethoxy)-1H-indole;
1-[(5-chlorothien-2-yl)sulfonyl]-4-(piperidin-2-ylmethoxy)-1H-indole;
1-[(3-fluorophenyl)sulfonyl]-4-(piperidin-2-ylmethoxy)-1H-indole;
1-[(2-fluorophenyl)sulfonyl]-4-(piperidin-2-ylmethoxy)-1H-indazole;
1-[(2-chlorophenyl)sulfonyl]-4-(piperidin-2-ylmethoxy)-1H-indazole;
1-[(5-chlorothien-2-yl)sulfonyl]-4-(piperidin-2-ylmethoxy)-1H-indazole;
4-(azepan-2-ylmethoxy)-1-(phenylsulfonyl)-1H-indole;
4-{[4-(azepan-2-ylmethoxy)-1H-indol-1-yl]sulfonyl}aniline;
4-(azepan-2-ylmethoxy)-1-[(2-fluorophenyl)sulfonyl]-1H-indole;
4-(azepan-2-ylmethoxy)-1-[(5-chlorothien-2-yl)sulfonyl]-1H-indole;
4-(azepan-2-ylmethoxy)-1-[(3-fluorophenyl)sulfonyl]-1H-indole;
4-(azepan-2-ylmethoxy)-1-[(2-fluorophenyl)sulfonyl]-1H-indazole;
4-(azepan-2-ylmethoxy)-1-[(2-chlorophenyl)sulfonyl]-1H-indazole;
4-(azepan-2-ylmethoxy)-1-[(5-chlorothien-2-yl)sulfonyl]-1H-indazole;
1-(phenylsulfonyl)-5-(pyrrolidin-2-ylmethoxy)-1H-indazole;
1-(phenylsulfonyl)-6-(pyrrolidin-2-ylmethoxy)-1H-indazole;
the stereoisomers thereof; and
the pharmaceutically acceptable salts thereof.
20. A process for the preparation of a compound of formula Ie
Figure US20050065185A1-20050324-C00027
wherein X, Y, Z, m, n, p, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are defined in claim 1 which comprises reacting a compound of formula XVI
Figure US20050065185A1-20050324-C00028
wherein X, Y, Z, m, n, p, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 are as defined hereinabove with a sulfonyl chloride, R12SO2Cl, wherein R12 is as defined hereinabove in the presence of a base optionally in the presence of a solvent.
21. A compound of formula XVI
Figure US20050065185A1-20050324-C00029
wherein
X is O, SOy or NR13;
Y is CR14 or N;
Z is CR15 or N with the proviso that when Y is N then Z must be CR15;
m is 0 or an integer of 1, 2 or 3;
n and p are each independently an integer of 1, 2 or 3;
R1 is halogen, CN, OR16, CO2R17, CONR18R19, CNR20NR21R22, SO2NR23R24, SOwR25, or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, phenyl or heteroaryl group each optionally substituted;
R2, R3, R5, R6, R7, R8, R9, R10 and R11 are each independently H or an optionally substituted C1-C6alkyl group;
R4 is H, CNR26NR27R28 or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl or cycloheteroalkyl group each optionally substituted;
R13 is H or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl aryl or heteroaryl group each optionally substituted;
R14 and R15 are each independently H, halogen or a C1-C6alkyl, aryl, heteroaryl or C1-C6alkoxy group each optionally substituted;
R16 is H, COR29 or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, aryl or heteroaryl group each optionally substituted;
R17 and R29 are each independently H or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
R18, R19, R20, R21, R22, R26, R27 and R28 are each independently H or an optionally substituted C1-C6alkyl group;
R23 and R24 are each independently H or a C1-C6alkyl, aryl or heteroaryl group each optionally substituted; and
R25 is an optionally substituted C1-C6alkyl, aryl, or heteroaryl group; or the stereoisomers thereof or the pharmaceutically acceptable salts thereof.
22. The compound according to claim 21 wherein X is O; Y is CR14; and n is 1.
23. The compound according to claim 22 wherein Z is CR15.
US10/949,061 2001-04-20 2004-09-24 Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands Abandoned US20050065185A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/949,061 US20050065185A1 (en) 2001-04-20 2004-09-24 Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28564401P 2001-04-20 2001-04-20
US10/126,805 US6831094B2 (en) 2001-04-20 2002-04-19 Heterocyclylalkoxy-,-alkylthio-and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
US10/949,061 US20050065185A1 (en) 2001-04-20 2004-09-24 Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/126,805 Division US6831094B2 (en) 2001-04-20 2002-04-19 Heterocyclylalkoxy-,-alkylthio-and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands

Publications (1)

Publication Number Publication Date
US20050065185A1 true US20050065185A1 (en) 2005-03-24

Family

ID=23095117

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/126,805 Expired - Fee Related US6831094B2 (en) 2001-04-20 2002-04-19 Heterocyclylalkoxy-,-alkylthio-and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
US10/949,061 Abandoned US20050065185A1 (en) 2001-04-20 2004-09-24 Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/126,805 Expired - Fee Related US6831094B2 (en) 2001-04-20 2002-04-19 Heterocyclylalkoxy-,-alkylthio-and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands

Country Status (17)

Country Link
US (2) US6831094B2 (en)
EP (1) EP1392682A2 (en)
JP (1) JP2004526781A (en)
KR (1) KR20030088507A (en)
CN (1) CN1293073C (en)
AR (1) AR034588A1 (en)
AU (1) AU2002309585B2 (en)
BR (1) BR0209047A (en)
CA (1) CA2444036A1 (en)
EA (1) EA200301143A1 (en)
HU (1) HUP0303801A2 (en)
IL (1) IL158448A0 (en)
MX (1) MXPA03009490A (en)
NO (1) NO20034647L (en)
PL (1) PL366639A1 (en)
WO (1) WO2002085853A2 (en)
ZA (1) ZA200309009B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100657056B1 (en) * 2002-06-05 2006-12-13 에프. 호프만-라 로슈 아게 5-6- 1--4- 1-sulfonyl-4-aminoalkoxy indole derivatives as 5-ht6-receptor modulators for the treatment of cns-disorders
BR0316962A (en) * 2002-12-03 2005-10-25 Hoffmann La Roche Aminoalkoxyindols as 5-ht6 receptor binders for the treatment of snc disorders
BRPI0407253A (en) * 2003-02-14 2006-01-31 Wyeth Corp Heterocyclyl-3-sulfonylindazoles as ligands 5-hydroxytryptamine-6 process for their preparation, their uses in the preparation of a pharmaceutical composition and a pharmaceutical composition comprising said compounds
SE0302760D0 (en) * 2003-10-20 2003-10-20 Biovitrum Ab New compounds
KR20080034497A (en) * 2005-08-15 2008-04-21 와이어쓰 Azinyl-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands
NZ565872A (en) * 2005-08-15 2011-06-30 Wyeth Corp Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands
CN101432274A (en) * 2006-04-05 2009-05-13 惠氏公司 Sulfonyl-3-heterocyclylindazole derivatives as 5-hydroxytryptamine-6 ligands
WO2007120596A1 (en) * 2006-04-12 2007-10-25 Wyeth DIHYDRO[1,4]DIOXINO[2,3-e]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS
AU2007255042A1 (en) * 2006-06-01 2007-12-13 Wyeth 1-sulfonylindazolylamine and -amide derivatives as 5-hydroxytryptamine-6 ligands
US20090023925A1 (en) * 2007-06-28 2009-01-22 Wyeth N'-(2-halobenzylidene)sulfonylhydrazides as intermediates in the manufacture of arylsulfonylindazoles
WO2011143430A1 (en) 2010-05-12 2011-11-17 Abbott Laboratories Indazole inhibitors of kinase
KR101594002B1 (en) 2010-10-06 2016-02-15 글락소스미스클라인 엘엘씨 Benzimidazole derivatives as pi3 kinase inhibitors
US9663498B2 (en) 2013-12-20 2017-05-30 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic compounds and their application in pharmaceuticals
JP6515175B2 (en) 2014-07-08 2019-05-15 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． Aromatic heterocyclic derivative and pharmaceutical application thereof
SG11202000602YA (en) 2017-08-01 2020-02-27 Theravance Biopharma R&D Ip Llc Pyrazolo and triazolo bicyclic compounds as jak kinase inhibitors
CA3125039A1 (en) 2019-01-23 2020-07-30 Theravance Biopharma R&D Ip, Llc Imidazo[1,5-a]pyridine, 1,2,4-triazolo[4,3-a]pyridine and imidazo[1,5-a]pyrazine as jak inhibitors
CN114901659A (en) 2019-11-26 2022-08-12 施万生物制药研发Ip有限责任公司 Fused pyrimidinone compounds as JAK inhibitors

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5037841A (en) * 1988-04-19 1991-08-06 Bayer Aktiengesellschaft 1,3-disubstituted pyrrolidines
US6054469A (en) * 1995-11-16 2000-04-25 Merck Sharp & Dohme Ltd. Substituted tetrahydropyridine derivatives acting on 5-HT receptors
US6509357B1 (en) * 2001-01-23 2003-01-21 Wyeth 1-aryl or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
US6716837B1 (en) * 1999-07-15 2004-04-06 Nps Allelix Biopharmaceuticals, Inc. Heterocyclic compounds for the treatment of migraine
US6767912B2 (en) * 2000-12-22 2004-07-27 Wyeth Heterocyclylindazole and -azaindazole compounds as 5-hydroxytryptamine-6 ligands
US6995176B2 (en) * 2002-07-18 2006-02-07 Wyeth 1-heterocyclylalkyl-3-sulfonyl-indole or -indazole derivatives as 5-hydroxytryptamine-6 ligands
US7238696B2 (en) * 2003-02-14 2007-07-03 Wyeth Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5274097A (en) * 1988-04-19 1993-12-28 Bayer Aktiengesellschaft 1,3-disubstituted pyrrolidines
GB9103862D0 (en) * 1991-02-25 1991-04-10 Glaxo Group Ltd Chemical compounds
TW288010B (en) * 1992-03-05 1996-10-11 Pfizer
JPH09505029A (en) * 1993-07-19 1997-05-20 藤沢薬品工業株式会社 Benzimidazole derivatives useful as dopamine receptor agonists, 5-HT receptor antagonists or α-lower 1 receptor antagonists
US5578716A (en) * 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
JPH0940646A (en) 1995-07-27 1997-02-10 Yamanouchi Pharmaceut Co Ltd Condensed benzene ring derivative or its salt
WO1998050346A2 (en) * 1997-04-18 1998-11-12 Smithkline Beecham Plc Acetamide and urea derivatives, process for their preparation and their use in the treatment of cns disorders

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5037841A (en) * 1988-04-19 1991-08-06 Bayer Aktiengesellschaft 1,3-disubstituted pyrrolidines
US6054469A (en) * 1995-11-16 2000-04-25 Merck Sharp & Dohme Ltd. Substituted tetrahydropyridine derivatives acting on 5-HT receptors
US6716837B1 (en) * 1999-07-15 2004-04-06 Nps Allelix Biopharmaceuticals, Inc. Heterocyclic compounds for the treatment of migraine
US6767912B2 (en) * 2000-12-22 2004-07-27 Wyeth Heterocyclylindazole and -azaindazole compounds as 5-hydroxytryptamine-6 ligands
US6509357B1 (en) * 2001-01-23 2003-01-21 Wyeth 1-aryl or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
US6995176B2 (en) * 2002-07-18 2006-02-07 Wyeth 1-heterocyclylalkyl-3-sulfonyl-indole or -indazole derivatives as 5-hydroxytryptamine-6 ligands
US7238696B2 (en) * 2003-02-14 2007-07-03 Wyeth Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands

Also Published As

Publication number Publication date
NO20034647D0 (en) 2003-10-17
AR034588A1 (en) 2004-03-03
CN1518548A (en) 2004-08-04
CA2444036A1 (en) 2002-10-31
WO2002085853A3 (en) 2002-12-19
WO2002085853A2 (en) 2002-10-31
EP1392682A2 (en) 2004-03-03
MXPA03009490A (en) 2004-02-12
ZA200309009B (en) 2005-02-21
US20030078286A1 (en) 2003-04-24
CN1293073C (en) 2007-01-03
BR0209047A (en) 2004-08-10
NO20034647L (en) 2003-11-20
PL366639A1 (en) 2005-02-07
HUP0303801A2 (en) 2004-03-01
KR20030088507A (en) 2003-11-19
AU2002309585B2 (en) 2008-01-31
US6831094B2 (en) 2004-12-14
EA200301143A1 (en) 2004-02-26
IL158448A0 (en) 2004-05-12
JP2004526781A (en) 2004-09-02

Similar Documents

Publication Publication Date Title
US6815456B2 (en) Heterocyclyloxy-, -thioxy- and -aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
US6710069B2 (en) 1-aryl- or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
US6831094B2 (en) Heterocyclylalkoxy-,-alkylthio-and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
US6613781B2 (en) Heterocyclylaklylindole or -azaindole compounds as 5-hydroxytryptamine-6 ligands
RU2347780C2 (en) Heterocyclyl-3-sulfonylindazoles as 5-hyroxytryptamine-6 ligands
US20080064684A1 (en) 1-Aryl- or 1-alkylsulfonyl-heterocyclybenzazoles as 5-hydroxytryptamine-6 ligands
KR20030040566A (en) 1-Aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
AU2002309585A1 (en) Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
US7541358B2 (en) 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
US6727270B2 (en) Pyrrolylalkylidene-hydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands
AU2002307424A1 (en) Heterocyclyloxy-, -thioxy- and -aminobenzazole derivatives as 5-hydroxytrypltamine-6 ligands
US20030225121A1 (en) Heterocyclylalkylindole or-azaindole compounds as 5-hydroxytryptamine-6 ligands
AU2008203389A1 (en) Heterocyclyloxy-, -thioxy- and - aminobenzazole derivatives as 5- hydroxytryptamine-6 ligands

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION